– USA, KS – Parnell Pharmaceuticals Holdings Ltd (Nasdaq:PARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced the appointment of Ellen B. Richstone and Dr. David K. Rosen to its Board of Directors.  The appointments increase the Board to six directors, and the number of independent directors to three.

“Parnell is excited to announce the appointment of Ellen Richstone and Dr. David Rosen to our Board,” said Dr. Alan Bell, Chairman of Parnell.  “These additions bring significant finance and animal pharmaceutical experience to our Company.  We welcome both Ellen and David and look forward to the contributions they will make to our organization”

Ms. Richstone will serve has the Chair of the Audit Committee and will sit on the Compensation and Governance Committees.  Dr. Rosen will Chair the Nominating and Governance Committee and will be a member of the Audit and Compensation Committees.

Ms. Richstone is a former private company CEO, Fortune 500 CFO (Rohr Aerospace) and Fortune 500 Treasurer (Data General).  Her industry experience includes:  Computer Hardware/Software; Communications; Industrial Products; Lighting and Semiconductors; as well as experience in Consumer Products, Automotive, Aerospace and Financial Services.

Ms. Richstone currently sits on three public company boards and previously sat on other public and private boards including an S&P 500 Company until its sale to a large global consumer products company.  She was awarded the first annual Distinguished Director Award from the American College of Corporate Directors in 2013, was named to the Top 100 Board Diversity Candidates for Public Companies and currently sits on the Board of the National Association of Corporate Directors – New England.

Ms. Richstone received her Bachelor of Arts in Political Science from Scripps College. She holds a Master of Arts in International Affairs and Masters of Law and Diplomacy from the Fletcher School of Law and Diplomacy at Tufts University. She also holds an advanced professional certificate in Finance from New York University’s Stern School of Business.

Dr. David Rosen is a healthcare executive with over 30 years of experience in the Animal Health, Pharmaceutical, Private Equity and Medical Device industries. He is currently President and CEO of eNeura Inc., a privately held medical device company specializing in the treatment and prevention of migraine headache. Dr. Rosen previously held senior executive positions as Founder, President and COO of Aratana Therapeutics, an animal health biopharmaceutical company and as Head of Corporate Out Licensing and Divestitures for Pfizer, Inc. in New York City.

Dr. Rosen has served on the Boards of Directors for several private companies including Ablative Solutions and AdjacentHealth Technologies as well as several not-for-profit organizations.

Dr. Rosen received a Bachelor of Science degree from the University of Wisconsin, Madison in Bacteriology and a Doctor of Veterinary Medicine degree from Iowa State University, College of Veterinary Medicine. He also earned a Board Certification in Feline Practice from the American Board of Veterinary Practitioners.

About Parnell

Parnell (PARN) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms – FETCH™ and mySYNCH®. These innovative technology solutions are designed to enhance the quality of life and/or performance of animals, while driving customers’ operational efficiency and profitability. Parnell distinguishes itself in the industry by providing value-added solutions that position the Company as a true partner to their customers.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.